Talks
T-DXd: Common side effects
October 20, 2026
DB04 outcomes in HER2 IHC 1+ vs 2+/ISH negative disease
October 20, 2026
DB04: Outcomes in TNBC subset
October 20, 2026
Destiny-Breast04: Primary results
October 20, 2026
DESTINY-Breast04 eligibility
October 20, 2026
DESTINY-Breast04: trial design and primary endpoint
October 20, 2026
DAISY: Early clues to T-DXd resistance
October 20, 2026
The DAISY trial evaluated how much HER2 is needed for T-DXd
October 20, 2026
Why HER2 low became targetable
October 20, 2026
HER2 results often differ between specimens
October 20, 2026
Reproducibility in HER2 testing
October 20, 2026
How common is HER2 low disease?
October 20, 2026
HER2 Ultralow: A subcategory of HER2 Low
October 20, 2026
Why HER2 Low is not a distinct biological subtype
October 20, 2026
The HER2 IHC Scoring System
October 20, 2026
IHC 1+ and IHC 2+/ISH negative: 2 paths to HER2 Low
October 20, 2026
What does HER2 low actually mean?
October 20, 2026
Close button
Why are you reporting this TALK?